People: Commonwealth Biotechnologies Inc (CBTEQ.PK)

CBTEQ.PK on OTC Markets Group

0.09USD
22 May 2013
Price Change (% chg)

$0.01 (+5.88%)
Prev Close
$0.09
Open
$0.09
Day's High
$0.09
Day's Low
$0.09
Volume
200
Avg. Vol
6,345
52-wk High
$0.12
52-wk Low
$0.01

Search Stocks

Summary

Name Age Since Current Position

Bill Guo

 46 2010 Chairman of the Board

Richard Freer

 67 2010 Chief Executive Officer, Chief Operating Officer, Director

Ashley Paul D'Sylva

 40 2009 Director

Maria Song

 41 2009 Director

James Causey

 57 2004 Independent Director

Samuel Sears

 68 2001 Independent Director

Eric Tao

 43 2009 Independent Director
» Insider Trading

Biographies

Name Description

Bill Guo

 Dr. Bill Guo is Chairman of the Board of Commonwealth Biotechnologies, Inc. He is the Chairman and founder of VenturePharm Group. He has over 10 years global pharmaceutical industry experience from researcher to senior executive in North America at Johnson & Johnson, Novapharm and VenturePharm Canada. He has over 9 years of experience as an entrepreneur in China. Mr. Guo was a Ph.D. candidate in the Department of Pharmaceutics and was awarded an MSc degree in industrial pharmacy from the University of Toronto, Toronto, Canada, an MBA program certificate from Herriot Watt University, Toronto, Canada, and an Executive education certificate from Judge Business School, University of Cambridge, UK. Fortune magazine recognized him as one of the top emerging entrepreneurs in China. He was also recipient of various rewards: 2005 National Hero awarded by the State Council of China; one of the ten management elites in China in 2004; one of the ten most influential individuals in business in China, 2005; distinguished entrepreneur awarded from overseas by government of China, 2005; sole winner of Youth Chinese Entrepreneur Award organized by Asia Business Week in 2003 and 2005 Entrepreneurs and innovation by BCC (British Chamber of Commerce).

Richard Freer

 Dr. Richard J. Freer, Ph.D., is Chief Executive Officer, Chief Operating Officer, Director of Commonwealth Biotechnologies, Inc. Since co-founding CBI in 1992, Dr. Freer has served as a director of CBI and, until 2008, as the Chairman of the Board of CBI. He assumed the role of Chief Operating Officer in 2002 and Chief Executive Officer in 2011. From 1975 until 1997, Dr. Freer was employed in the Department of Pharmacology and Toxicology at Virginia Commonwealth University (“VCU”), first as an Associate Professor and then a full Professor. In addition, from 1988 through 1995, Dr. Freer was first Director and then Chair of the Biomedical Engineering Program. From 1996 through 1997, Dr. Freer served as Professor in VCU’s Department of Biochemistry and Molecular Biophysics. Dr. Freer received a bachelor’s degree in Biology from Marist College and a doctorate degree in Pharmacology from Columbia University.

Ashley Paul D'Sylva

 Dr. Ashley Paul D'Sylva, Ph.D., is Director of Commonwealth Biotechnologies, Inc. Dr. D’Sylva assumed the position of Chief Executive Officer of CBI in January 2007 and served in that position until 2009. Dr. D’Sylva served previously as the co-founder and Managing Director of PharmAust Limited. From 2001 to 2005, Dr. D’Sylva served as Director of Research and Development at Murdoch University. Dr. D’Sylva has a track record in raising investment capital for early stage business ventures and has led the development of a number of research joint-venture institutes, companies and funds. He sits on the advisory board of the Centre for Computational Comparative Genomics, a joint-venture research institute in Bioinformatics based at Murdoch University and retains a non-executive role at Murdoch University as an Adjunct Professor of Business. He received a Ph.D. from the University of Arizona in public finance and econometrics.

Maria Song

 Ms. Maria Song, M.D., Ph.D., is Director of Commonwealth Biotechnologies, Inc., since March 27, 2009. On March 27, 2009, CBI appointed Dr. Maria Song, Chairman of VPS Global, to CBI’s Board of Directors. Dr. Song previously served as the General Manager of a Sino-Hong Kong joint venture pharmaceutical company. Dr. Song has over fifteen years of experience in drug development and has conducted a number of multi-center clinical trials, local registration trials, and Phase IV studies for a variety of international clients. Dr. Song is also has experience on regulatory submissions to the Chinese State Food and Drug Administration (“SFDA”) and often advises the SFDA on policy matters. Dr. Song received her M.D. and Ph.D. from the University of Peking Union Medical College. Dr. Song also received a Master of Economics degree from the Central University of Finance and Economics.

James Causey

 Mr. James D. Causey is Independent Director of Commonwealth Biotechnologies, Inc. Since 2004, Mr. Causey has served as Vice President of Trader Publishing Company, a nationwide network of classified publications. From 2003 until 2004, Mr. Causey served as a consultant in the publishing industry. From 1999 to 2003, Mr. Causey served as the chief executive officer of Sabot Publishing, a Richmond, Virginia based publisher of special interest publications. Mr. Causey received a master’s degree in business from the University of Maryland.

Samuel Sears

 Mr. Samuel P. Sears, Jr., is Independent Director of Commonwealth Biotechnologies, Inc. Since March 1999, Mr. Sears has been in private practice as an attorney and has been providing business consulting services. From December 1998 through February 1999, Mr. Sears served as Vice Chairman of American Prescription Providers, Inc., a specialty pharmacy network offering prescriptions and nutriceuticals to patients with chronic diseases. From 1995 through May 1998, Mr. Sears was Chief Executive Officer and Chairman to Star Scientific, Inc., a tobacco company focusing on demonstrating the commercial viability of potentially less harmful tobacco products. Mr. Sears is a graduate of Harvard College and Boston College Law School. Mr. Sears is currently managing partner of the law firm of Cetrullo and Capone, PC, Boston, MA.

Eric Tao

 Mr. Eric V. Tao is Independent Director of Commonwealth Biotechnologies, Inc., since January 23, 2009. On January 23, 2009, CBI appointed Mr. Eric Tao, Director and Chief Investment Officer of AGI Capital Group, Inc., to CBI’s Board of Directors. Mr. Tao graduated from Pomona College in 1989 and the University of California Hastings College of Law in 1995. In addition to his position with AGI Capital Group, Inc., Mr. Tao also serves as a member of the Board of Directors of Avant Housing, Hukilau, LLC, the Hawaii Chamber of Commerce of Northern California and the San Francisco YB Community Benefit District.

Basic Compensation

Name Fiscal Year Total

Bill Guo

 --

Richard Freer

 153,976

Ashley Paul D'Sylva

 269,039

Maria Song

 --

James Causey

 --

Samuel Sears

 --

Eric Tao

 --
As Of 30 Dec 2011

Options Compensation

Name Options Value

Bill Guo

 0 0

Richard Freer

 159,649 56,594

Ashley Paul D'Sylva

 0 0

Maria Song

 0 0

James Causey

 0 0

Samuel Sears

 0 0

Eric Tao

 0 0

Insider Trading

Name Shares Traded Price

FREER RICHARD J

 2,846,715 $0.05

SEARS SAMUEL P JR

 372,263 $0.05

FREER RICHARD J

 2,025,000 $0.02
» Full list on Insider Trading
Search Stocks